Axxess Pharma, Inc. Retains A-Z Pharma for Strategic Consultancy Services to Accelerate International Expansion of Product Sales
18 November 2010 - 1:30AM
Marketwired
Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company
specializing in the marketing and distribution of both prescription
and non-prescription medical products, is pleased to announce A-Z
Pharma, Inc. has been retained by the company under a comprehensive
consultancy agreement.
In this context, Axxess Pharma will be working closely with Ms.
Rahma Mbarki, Vice President of Marketing and Sales at A-Z Pharma.
Ms. Mbarki has over 18 years of professional experience, of which
10 years is in the pharmaceutical industry. Ms. Mbarki's experience
includes drug development, regulatory affairs, process control,
contract preparation, negotiation and management, private financing
for R&D, and introduction of new products to North America,
Latin America, South East Asia, Middle East and North Africa for
substantial year over year residual sales growth.
A-Z Pharma's primary responsibilities for Axxess Pharma will
be:
1. Sourcing and securing in-licensing product opportunities; 2.
Seeking product portfolio expansion and out-licensing; 3. Finding
potential customers for the products of Axxess Pharma in the
Territory; 4. Providing assistance in price negotiations with
customers; 5. Conducting business review and monitor progress with
selected partners; 6. Follow up on logistics; 7. Assist in the
registration processes with Health Canada for the products sourced
by A-Z Pharma; 8. Assist with marketing activities (help getting
promotional materials and selling aids from the suppliers found by
A-Z Pharma).
"We are pleased to engage and integrate A-Z Pharma's proven
services into the exciting things we are looking to accomplish with
our company. Their extensive international experience and support
will be instrumental, from product development to international
product distribution and sales. We have a large product line which
is set to hit the market in the coming months. A-Z Pharma will be
working closely with our company to ensure strong long-term global
sales," stated Gerald Sequeira, President.
For more information, please contact Investor Relations at (973)
351-3868.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that
focuses on the marketing of dermatological, therapeutic
nutritionals, pain management and diagnostic products in Canada and
abroad since 1997. Axxess owns 22 established pharmaceutical
prescription products that have proven sales in Canada and
internationally. The company has an experienced management team and
field sales force to market products nationally to hospitals and
retail pharmacies as well as specialized practice areas including
Dermatology and Nephrology,Neurology and Urology.
Safe Harbor
Statements about the Company's future expectations and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby.
The above information contains information relating to the
Company that is based on the beliefs of the Company and/or its
management, as well as assumptions made by any information
currently available to the Company or its management. When used in
this document, the words "anticipate," "estimate," "expect,"
"intend," "plans," "projects," and similar expressions, as they
relate to the Company or its management, are intended to identify
forward-looking statements. Such statements reflect the current
view of the Company regarding future events and are subject to
certain risks, uncertainties and assumptions, including the risks
and uncertainties noted. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
to be incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated, expected,
intended or projected. In each instance, forward-looking
information should be considered in light of the accompanying
meaningful cautionary statements herein. Factors that could cause
results to differ include, but are not limited to, successful
performance of internal plans, the impact of competitive services
and pricing and general economic risks and uncertainties.
Contact: Taylor Capitol, Inc. Investor Relations Stephen Taylor
973-351-3868 info@theStockAlerts.com www.thestockalerts.com
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jul 2023 to Jul 2024